

KIDNEY


Kidney, Obesity, Diabetes

2024

VIRTUAL CONFERENCE

To register : www.Kidney2024.com

Saturday, February 3rd, 2024 | 10:00 h - 16:50 h EST



Louise Moist,
MD, MSc, CCPE, FRCPC
CO-CHAIR
Western University, London, ON



Andrew W. Steele,
MD, FRCPC
CO-CHAIR
Queen's University, Kingston, ON


FACULTY




Sofia B. Ahmed,
MD, MMSc, FRCPC
University of Alberta,
Edmonton, AB



David Z. I. Cherney,
MD CM, PhD, FRCPC
University of Toronto,
Toronto, ON




Michael T. Chiu,
MD, MScHQ, FRCPC
Western University,
London, ON




Kristin K. Clemens,
MD, MSc, FRCPC
Western University,
London, ON




Dervla Connaughton,
MB MCh, BAO, LRCPI&SI (Hons), MSc, PhD
Western University,
London, ON



Jocelyn S. Garland,
MD, FRCPC
Queen's University,
Kingston, ON




John S. Gill,
MD, MS, FRCPC
University of British Columbia,
Vancouver, BC




Robert A. Hegele,
MD, FRCPC, FACP, FAHA, FCAHS, FCCS
Western University,
London, ON




Philip A. McFarlane,
MD CM, PhD, FRCPC
University of Toronto,
Toronto, ON




Vlado Perkovic,
MBBS, PhD, FASN, FRACP
University of New South Wales,
Sydney, NSW, Australia




Normand Proulx,
MD, FRCPC
McGill University,
Montreal, QC




Mukul (Mike) Sharma,
MD, MSc, FRCPC
McMaster University,
Hamilton, ON



Navdeep Tangri,
MD, PhD, FRCPC
University of Manitoba,
Winnipeg, MB



Sheldon W. Tobe,
MD, MScCH (HPTe), FRCPC, FACP, FASH
University of Toronto, Toronto, ON
Northern Ontario School of Medicine,
Sudbury, ON



Subodh Verma,
MD, PhD, FRCSC, FAHA
University of Toronto,
Toronto, ON

AGENDA * ALL TIMES ARE EST

10 00 **Welcome and Opening Remarks** Dr. Louise Moist
10 10 **PLENARY 1: Kidney Risk Scores** Dr. Navdeep Tangri

10 30 **Q&A**

The Metabolic Kidney

10 40 **Fatty Kidney, Obesity and CKD** Dr. Louise Moist
10 55 **GLP-1R-based Co-agonists and CKD** Dr. David Cherney
11 10 **Lipid Lowering in CKD** Dr. Robert Hegele
11 25 **Guideline Updates: CKD and Type 2 Diabetes** Dr. Sheldon Tobe

11 40 **Q&A**

12 10 **PLENARY 2: EDI in CKD - Implications for Treatment and Research** Dr. Sofia Ahmed

12 30 **Q&A**

12:40 **Break**

The Cardiorenal Axis

13 15 **Aldosterone - The Forgotten A in RAAS Inhibition: Implications in CKD and Resistant Hypertension** Dr. Philip McFarlane
13 30 **Intersection of Kidney Disease and Heart Failure** Dr. Subodh Verma
13 45 **Anticoagulation in CKD – Factor XI** Dr. Mukul (Mike) Sharma

14 00 **Q&A**

14 20 **PLENARY 3: Inflammation and CKD** Dr. Vlado Perkovic

14 40 **Q&A**

Kidney Potpourri

14 50 **Glomerulonephritis for Beginners – TTP, HUS and the Complement System** Dr. Jocelyn Garland

15 05 **Pre- and Post-Kidney Transplantation – What You Need to Know In 2024** Dr. John Gill

15 20 **Potassium and CKD – Tricks of the Trade** Dr. Michael Chiu

15 35 **Genetic Kidney Disease – Finding and Treating Patients** Dr. Dervla Connaughton

15 50 **Diagnosing and Treating Osteoporosis in CKD** Dr. Kristin Clemens

16 05 **Anemia in Kidney Disease – How and Why to Mix the Old with the New** Dr. Normand Proulx

16 20 **Q&A**

16 50 **Closing Remarks** Dr. Andrew Steele

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Association of Pathologists-Association Canadienne des pathologistes. You may claim a maximum of 6.0 hours (credits are automatically calculated).

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.ama-assn.org/go/internationalcme. Live educational activities recognized by the Royal College of Physicians and Surgeons of Canada as Accredited Group.

LEARNING OBJECTIVES

At the conclusion of this program, attendees will be able to:

- Compare the available tools for assessing kidney risk.
- Recognize the importance and implications of EDI factors in kidney medicine.
- Explain the role of inflammation in the pathophysiology and as a therapeutic target for kidney disease.
- Describe the metabolic comorbidities of kidney disease and the recommended therapies and treatment goals for supporting metabolic health.
- List the cardiovascular considerations in kidney disease and the emerging cardiorenal therapeutic strategies.
- Discuss recent advances in kidney medicine for genetic diseases, transplantation, potassium management, osteoporosis and anemia.

CMS CANADIAN MEDICAL & SURGICAL
KNOWLEDGE TRANSLATION RESEARCH GROUP
A Not-for-Profit Physician Organization Specializing in Research and Education

This educational initiative is developed by the Canadian Medical & Surgical Knowledge Translation Research Group (CMS)